Leading SPO Firm Sciformix Continues Global Expansion with Opening of New Manila Office to Accommodate Rapid Growth
Sciformix Corporation, a leading Scientific Process Organization (SPO) has announced the opening of their new offices located in Manila, the Philippines. The expansion into Manila comes as part of Sciformix‘s continued growth and provides the opportunity for the company to utilise the region’s extensive resource of talented medical professionals. Philippine Labor and Employment Secretary, Rosalinda Baldoz, welcomed the move by Sciformix and the opportunity for medical professionals to remain in the Philippines with attractive salaries and career opportunities.
“Sciformix’s continued growth and success has created an opportunity for our expansion into Manila, which is an important piece of our strategy and global footprint. As a leading SPO, this move takes us forward with the goal of adding more than 200 highly skilled employees in the Philippines,” said Manish Vinayak Soman, Sciformix President and Chief Executive Officer (CEO).
Sciformix, recent winner of Frost & Sullivan’s Pharmaceutical Knowledge Process Outsourcing (KPO) Entrepreneurial Company of the Year award, has experienced remarkable growth to become an SPO, a sub-category of KPO specialising in life sciences. The company’s investment in its people and technologies has enabled the business to deliver its clients differentiated services, resulting in rapid double digit revenue growth. Sciformix has a unique positioning as a SPO, in that it combines deep expertise in workflow processes optimisation with scientific knowledge, which delivers in line with their cost efficiency model.
This expansion into the Philippines also sees Sciformix as the first company based in Manila to undertake case management activities. A 135-strong team from Sciformix’s Philippines and India centers is supporting one of its Fortune 100 company clients that specializes in consumer healthcare, medical devices and diagnostics, and pharmaceuticals.
Sciformix, headquartered in the US, with operations in India and the Philippines, partners with life science organisations through the entire drug development cycle to provide a full range of services from study design to post marketing surveillance and commercialisation support. Areas of specialisation include Safety and Risk Management, Clinical Research & Post Approval Services, Medical Affairs, Scientific Writing and Regulatory Affairs.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance